NTRA Q2 2023 Earnings — Natera, Inc. Revenue & Financial Results | Market Cap Arena

NTRANatera, Inc.

$29B

Q2 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$261M+31.9% YoY

Gross Profit

$118M45.2% margin

Operating Income

-$112M-43.0% margin

Net Income

-$111M-42.4% margin

EPS (Diluted)

$-0.97

QoQ Revenue Growth

+8.1%

Cash Flow

Operating Cash Flow

-$79M

Free Cash Flow

-$87M

Stock-Based Comp.

$44M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$652M

Stockholders' Equity

$596M

Cash & Equivalents

$381M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$261M	$198M	+31.9%
Gross Profit	$118M	$89M	+32.9%
Operating Income	-$112M	-$143M	+21.4%
Net Income	-$111M	-$145M	+23.7%

Revenue Segments

Product

$258M86%

Royalty

$20M7%

Oncology products

$19M6%

Licensing and other

$3M1%

Geographic Segments

United States

$253M97%

Europe, Middle East, India, Africa

$6M2%

Asia Pacific and Other

$1M0%

Americas, excluding U.S.

$1M0%